Cellectis to Present at the 2017 Annual Conference of the American Association for Cancer Research

New York, N.Y. – March 29, 2017 – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that data on its gene-edited allogeneic CAR T-cells will be presented at the American Association for Cancer Research (AACR) Annual Meeting. This includes both wholly-controlled Cellectis programs and Pfizer/Cellectis collaboration programs. The meeting will be held from April 1st to April 5th, 2017 in Washington, D.C., USA.

Cellectis presentation:

- **UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia Targeting CD22 with CAR T-cells**
-

Agnès Gouble[1], Cécile Schiffer-Mannioui[1], Séverine Thomas[1], Anne-Sophie Gautron[1], Laurent Poirot[1], Julianne Smith[2].
[1]Cellectis, Paris, France; [2]Cellectis, New York, NY

Innate Effectors in Immunity to Cancer session – section 30
April 4, 2017, 8:00 AM - 12:00 PM Eastern Time

Pfizer/Cellectis presentations:

- **Allogeneic EGFRvIII Chimeric Antigen Receptor T Cells for Treatment of Glioblastoma**

Oi Kwan Wong[1], Mathilde Dusseaux[2], Jing-Tyan Ma[1], Melinda Au[1], Sophie Leduc[2], Joyce Chou[1], Jessica M. Yu[1], Marjorie Bateman[1], Thomas Pertel[1], Kevin C. Lindquist[1], Julianne Smith[3], Barbra Sasu[1], Shu-Hui Liu[1].
[1]Pfizer Inc., South San Francisco, CA; [2]Cellectis, Paris, France; [3]Cellectis, New York, USA

Innate Effectors in Immunity to Cancer session – section 30
April 4, 2017, 8:00 AM - 12:00 PM Eastern Time

- **Differential modulation of the PD-1 pathway impacts the anti-tumor activity of CAR T cells**

Regina J. Lin[1], Anne-Sophie Gautron[2], Laurent Poirot[2], Oi Kwan Wong[1], Barbra Sasu[1], Bijan Boldajipour[1].
[1]Pfizer, South San Francisco, CA; [2]Cellectis, Paris, France; [3]Cellectis, New York, USA

Late-Breaking Research: Immunology session – section 35
April 4, 2017, 8:00 AM - 12:00 PM Eastern Time

Collaboration with Pfizer
In June 2014, Cellectis and Pfizer began collaborating on a joint clinical development program for UCAR-T therapies, in the field of oncology, directed at numerous targets selected by Pfizer and several targets selected by Cellectis.

About Cellectis
Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 17 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases as well as its pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group

For further information, please contact:

Media contacts:
Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241,
ckasunich@kcsa.com

IR contact:
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,
simon.harnest@cellectis.com

Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

# # #